First Manhattan’s abrdn Life Sciences Investors HQL Stock Holding History

First Manhattan’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,476	Closed	-$50K	–	1400
2018 Q3	$50K	Hold	2,476	–	–	﹤0.01%	981
2018 Q2	$46K	Buy	+2,476	New	+$46.6K	﹤0.01%	966

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

First Manhattan's HQL Position: Q4 2018 in Review

First Manhattan sold out of abrdn Life Sciences Investors (HQL) in Q4 2018, closing a stake of 2,476 shares — an estimated $50K sold.

First Manhattan first reported a position in HQL in Q2 2018 and held it in 2 quarters. The position peaked at $50K in Q3 2018. 59 funds tracked by Wall St. Rank hold HQL as of Q4 2018.

First Manhattan reported no remaining abrdn Life Sciences Investors position as of Q4 2018 after selling out during the quarter.
First Manhattan sold 2,476 abrdn Life Sciences Investors shares in Q4 2018, an estimated $50K.
First Manhattan first reported a position in abrdn Life Sciences Investors in Q2 2018 and held it in 2 quarters.
First Manhattan's abrdn Life Sciences Investors position peaked at $50K in Q3 2018.
59 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2018.

Based on First Manhattan's 13F filing for Q4 2018, filed 30 Jan 2019.